Brief: Arch Biopartners Enters Exclusive License Agreement With The University Of Cincinnati
24/03/2021 12:28
March 24 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ENTERS EXCLUSIVE LICENSE AGREEMENT WITH
THE
UNIVERSITY OF CINCINNATI FOR AB569 TOPICAL WOUND TREATMENT
Source text for Eikon: ID:nGNX4TJ6NL
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide